立体定向与标准肿瘤放疗在不可切除局部晚期非小细胞肺癌联合度伐利尤单抗维持治疗中的比较:一项倾向性评分匹配的多中心研究
该多中心回顾性研究纳入208例不可切除局部晚期非小细胞肺癌患者,其中21例(10%)接受肿瘤立体定向体部放疗(T-SBRT)联合纵隔常规分割放疗。
要点
- 两组急性3级毒性相当,无4-5级事件,但样本量有限需谨慎解读。
核心结论
- 在不可切除局部晚期非小细胞肺癌中,肿瘤立体定向体部放疗联合度伐利尤单抗维持治疗与更长的无进展生存期显著相关,总生存期有延长趋势,且未增加毒性。
研究设计与样本
- 多中心回顾性研究纳入2017年7月至2023年1月间208例不可切除局部晚期非小细胞肺癌患者,其中21例(10%)接受T-SBRT,采用倾向性评分匹配限制混杂效应。
主要发现
- 急性3级毒性两组相当,无4-5级事件发生。
关键数值与推荐
- 入组患者接受≥60 Gy常规分割放疗、≥1周期化疗及≥1周期度伐利尤单抗。
- T-SBRT组接受纵隔常规分割放疗及原发肿瘤超低分次照射,最常见SBRT方案为50 Gy分5次(28.6%)。
- 中位年龄64.0岁,多数为腺癌(59.1%)。
临床怎么用
- 对于不可切除局部晚期非小细胞肺癌,在常规放化疗联合度伐利尤单抗维持治疗基础上,可考虑对原发肿瘤追加立体定向体部放疗以改善无进展生存,但需注意证据为回顾性探索性。
局限性
- T-SBRT组患者数量有限(21例),结果应谨慎解读并视为探索性。
- 回顾性多中心设计,尽管采用倾向性评分匹配,仍可能存在残余混杂。
- 需进一步研究确定最佳时机和免疫协同作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor control in locally advanced non-small cell lung cancer (LA-NSCLC) is associated with patient prognosis, sustaining ongoing research in dose-escalation strategies. This study evaluates the efficacy and safety of tumor stereotactic body radiation therapy (T-SBRT) compared with tumoral normofractionated chemoradiation therapy followed by immunotherapy. METHODS AND MATERIALS: This retrospective multicenter study included patients with unresectable LA-NSCLC treated between July 2017 and January 2023. Eligible patients received ≥60 Gy normofractionated radiation therapy, ≥1 cycle of chemotherapy, and ≥1 cycle of durvalumab. The T-SBRT group received mediastinal normofractionated radiation therapy and ultrahypofractionated primary tumor irradiation. Propensity score matching (PSM) was performed to limit confounding effects. RESULTS: Among the 208 included patients, 21 (10%) received T-SBRT. Median age was 64.0 years, and most had adenocarcinoma (59.1%). There were no differences in patients' characteristics except stages and T stages (not observed in T stage after PSM). The most frequent SBRT regimen was 50 Gy in 5 fractions (28.6%). After a median follow-up of 38 months (95% CI, 26.0-57.0), T-SBRT was associated with longer progression-free survival in overall cohort (median not reached vs 22.8 months; hazard ratio [HR] = 0.46; 95% CI 0.21-0.99; P = .046), and after PSM (HR = 0.41; 95% CI, 0.18-0.92; P = .031). T-SBRT also tended to be associated with longer overall survival in both overall and PSM cohorts (HR = 0.54, 95% CI 0.22-1.33, P = .18; HR = 0.46, 95% CI, 0.18-1.18, P = .11, respectively). Acute grade 3 toxicities were comparable, without grade 4-5 events. However, given the limited number of patients, these results should be interpreted with caution and considered exploratory. CONCLUSIONS: T-SBRT in LA-NSCLC is significantly associated with longer progression-free survival with a trend toward prolonged overall survival, without increasing toxicity. Further studies are needed to refine optimal timing and immunologic synergy.
引用
- Cedoz E, Levy A, Martel-Lafay I, et al. Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching. Int J Radiat Oncol Biol Phys. 2025. PMID: 41138789. doi:10.1016/j.ijrobp.2025.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。